ACE inhibitors and ARBs are used globally from numerous people for various diseases such as hypertension, heart failure, coronary artery disease, or kidney disease12 Due to considerations of biological plausibility and a large percentage of COVID-19 patients with cardiovascular disease having a poor disease progression, speculation exists about the worse outcome of patients on long-term therapy with these agents. This evidence concerns the gene ACE and COVID-19.